Metaplastic Breast Cancer: Current Understanding and Future Directions

Area of Science:

• Oncology
• Genomics
• Translational Research

Background:

• Metaplastic breast cancers (MBC) are a heterogeneous group of rare breast tumors.
• MBC often present at advanced stages and are associated with poorer survival rates compared to common breast cancers.
• While predominantly triple-negative, understanding MBC's diverse subtypes and molecular landscape is crucial.

Purpose of the Study:

• To review the epidemiology, clinical presentation, and molecular characteristics of metaplastic breast cancers.
• To explore potential therapeutic targets and novel treatment strategies for MBC.
• To highlight the role of advanced research tools in understanding and treating these rare tumors.

Main Methods:

• Literature review of epidemiological data and clinical studies on MBC.
• Analysis of molecular profiling data, including genetic alterations and pathway involvement.
• Examination of treatment outcomes and emerging therapeutic approaches.

Main Results:

• MBC represent 0.2% to 1% of US breast cancers, often diagnosed at later stages.
• Triple-negative phenotype is most common; hormone receptor status is not prognostic, while HER2-positive MBC shows better outcomes.
• Overrepresented molecular features include DNA repair deficiencies, PIK3/AKT/mTOR, and WNT pathway alterations, with emerging targets for antibody-drug conjugates.

Conclusions:

• Metaplastic breast cancers require specialized treatment approaches due to their aggressive nature and unique molecular profile.
• Targetable molecular alterations present opportunities for novel therapies, including antibody-drug conjugates.
• Advanced research methodologies like big data and AI are essential for overcoming challenges in studying and treating uncommon tumors like MBC.